U.S. Wireless Telecom Stock News

NasdaqGS:SFNC
NasdaqGS:SFNCBanks

Stronger Q2 Results And Share Buyback Might Change The Case For Investing In Simmons First (SFNC)

Simmons First National Corporation recently reported past second-quarter 2026 results, with net interest income of US$200.63 million, net income of US$66.69 million and net loan charge-offs of US$9.12 million, all measured against the same period a year earlier. The bank also completed a repurchase of 700,000 shares for US$15.06 million, a capital allocation move that sits alongside higher earnings and lower loan charge-offs to shape how investors assess its financial profile. We’ll now...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

TTM’s Farnborough AI Data Center And Defense Showcase Could Be A Game Changer For TTM Technologies (TTMI)

In July 2026, TTM Technologies presented its aerospace, defense, and advanced electronics capabilities at the Farnborough International Airshow in the United Kingdom, highlighting its mission systems, RF components, and complex PCB solutions for global customers. The event underscored TTM's growing role in supplying high-end electronics for AI data center infrastructure and mission-critical defense hardware, reinforcing its position in these specialized markets. We’ll now examine how TTM’s...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

3 U.S. Pharma Stocks Worth Watching After New Import Tariffs

Tariffs are moving again, and that can quickly change the risk and reward profile for U.S. manufacturers. With new charges on Brazilian and Canadian imports, ongoing levies on metals, autos, timber and semiconductors, and a fresh 100% tariff on many pharmaceuticals, investors are asking which domestic producers might stand to benefit. This article looks at stocks from a U.S. Domestic Manufacturing Stocks screener that are closely exposed to these tariff shifts, and will walk through 3...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy

Axsome Therapeutics reported that the FDA has accepted its New Drug Application for AXS-12 for the treatment of cataplexy in narcolepsy. The FDA does not plan to hold an advisory committee meeting as part of the review. The filing acceptance marks a key regulatory step for AXS-12, a potential option for a serious sleep disorder with unmet medical need. For Axsome Therapeutics (NasdaqGM:AXSM), this regulatory milestone arrives with the stock trading around $239.62 and a very large 3 year and...
NYSE:URI
NYSE:URITrade Distributors

United Rentals (URI) Stock May Be Pricey Despite Its 229% Run

United Rentals stock has delivered a strong 229.4% return over the past five years, yet its valuation checks are sending mixed messages, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a premium while market multiples lean the other way. For investors trying to assess what the current US$1,035.06 share price really reflects, the split between these frameworks is central. Over five years United Rentals has returned 229.4%, which puts extra focus on whether recent...
NasdaqGS:SLDE
NasdaqGS:SLDEInsurance

Founder Led Stocks With Growth Stories Retail Investors Should Watch

With inflation, energy prices and interest rate expectations all pulling markets in different directions, many investors are looking for leaders whose interests are closely tied to long term outcomes rather than short term headlines. Founder led companies can fit that brief, as founders often have more of their own wealth, reputation and time invested in the business. This article looks at a curated Founder Led Companies screener that focuses on leaders who are personally committed to...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck (MRK) Gets Fresh KEYTRUDA Momentum In EU Testing And Biliary Cancer Trials

Merck (NYSE:MRK) is seeing new clinical progress for its KEYTRUDA franchise in Europe and in hard to treat cancers. Agilent received EU approval to use its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic to identify patients eligible for KEYTRUDA in additional gynecologic cancers. Phanes Therapeutics expanded its clinical trial collaboration with Merck to study KEYTRUDA in combination regimens for biliary tract cancer. These updates highlight how Merck is continuing to develop...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Is Affirm Holdings (AFRM) Fairly Valued As Bernstein Starts Coverage?

Affirm Holdings (AFRM) is back in focus after Bernstein initiated coverage with an Outperform rating, spotlighting the buy now pay later provider’s position across 27 million users and 515,000 merchants worldwide. See our latest analysis for Affirm Holdings. Affirm Holdings’ share price has cooled recently, with a 1-day share price return showing a 1.08% decline and a 7-day share price return showing a 9.54% decline, yet the 90-day share price return of 17.36% and 1-year total shareholder...
NYSE:ELAN
NYSE:ELANPharmaceuticals

The Bull Case For Elanco Animal Health (ELAN) Could Change Following New Tick-Prevention Data For Credelio

Recent data published in Parasites & Vectors showed that Elanco Animal Health’s Credelio QuattroTM kills black-legged and lone star ticks faster and more consistently over 28 days than rival products Simparica Trio and NexGard Plus, while also carrying a U.S. FDA-approved claim for preventing Lyme disease in dogs via rapid tick kill. The studies highlight that Credelio Quattro uniquely maintains an 8-hour speed of kill for black-legged ticks through Day 28, which directly targets the early...
NYSE:HLI
NYSE:HLICapital Markets

Houlihan Lokey (HLI) Stock Looks Undervalued On Fair Value Yet Overvalued On Earnings

Houlihan Lokey stock has delivered a 76.5% total return over the past five years, yet its current valuation picture is split, with the Excess Returns intrinsic value estimate pointing to upside while earnings based multiples suggest the shares trade at a richer level. Over five years, a 76.5% return suggests Houlihan Lokey has rewarded patient shareholders, even though the share price has recently been under pressure. For a specialist advisory firm like Houlihan Lokey, expectations for...
NYSE:CHD
NYSE:CHDHousehold Products

Church & Dwight (CHD) Nears Earnings, Is It Still Below Fair Value?

Church & Dwight (CHD) is back in focus as investors look ahead to its late July second quarter earnings release, following a series of upside surprises and ongoing margin focused productivity efforts. See our latest analysis for Church & Dwight. At a share price of $97.13, Church & Dwight has a 1-month share price return of 3.62% and a year to date share price return of 17.53%. Its 1-year total shareholder return of 1.38% suggests recent momentum has been stronger in the short term than over...
NYSE:KTB
NYSE:KTBLuxury

How Kontoor’s Comfort-Focused Denim Launches Could Shape Kontoor Brands (KTB) Investors’ Thesis

Earlier in July 2026, Kontoor Brands’ Lee label introduced the LQD Denim collection in the US and Europe, while Wrangler unveiled Toughlite, a lighter-weight, airflow-focused take on its Cowboy Cut jeans, both positioned as premium yet versatile denim offerings with prices around $70–$130. These product launches highlight Kontoor’s emphasis on fabric innovation and comfort-led design to broaden where and how its core denim brands can be worn, from work to more polished social settings. We’ll...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Does Enovix (ENVX) Elevating an Ex-Apple Operator Reframe Its Global Scaling Narrative?

Enovix Corporation announced that Dr. Michael Vyvoda, a former Apple Product Operations Director who helped scale AirPods manufacturing, joined as Chief Operating Officer on July 29, 2026, taking charge of global manufacturing, supply chain and operations engineering across Malaysia, Korea and India. By consolidating key operations leaders under a single COO with deep high-volume manufacturing experience, Enovix is signaling a reinforced focus on execution as it expands global...
NYSE:RDDT
NYSE:RDDTInteractive Media and Services

Is Reddit (RDDT) A Bargain Following Google AI Licensing Renewal Doubts?

Reports that Reddit (RDDT) may restrict Google’s access to its content for AI training have pushed the company’s US$60 million a year licensing deal into focus for investors. See our latest analysis for Reddit. The share price reaction to the Google licensing headlines has been sharp, with Reddit’s 1 day share price return down 8.32% and 7 day share price return down 13.96%. At the same time, the 90 day share price return of 11.39% and 1 year total shareholder return of 16.62% point to...
NasdaqGM:CAMT
NasdaqGM:CAMTSemiconductor

Camtek (CAMT) Leans On AI Packaging Growth As Valuation Questions Build

Camtek (CAMT) has drawn attention after recent trading produced mixed short term moves, with the stock up about 0.4% in the latest session but down roughly 7% over the past month. See our latest analysis for Camtek. Zooming out, Camtek’s share price has the latest close at $156.79, with recent weakness over the past three months contrasting with a much stronger year to date share price return and very large five year total shareholder return. This suggests long term momentum, while near term...
NYSE:NU
NYSE:NUBanks

Nu Holdings (NU) Stock Looks Overvalued As Its 85% Run Continues

Nu Holdings has delivered an 84.8% return over the past three years, yet its valuation signals are split, with an Excess Returns intrinsic value estimate suggesting about 11.1% upside while market multiples lean toward the stock looking expensive. Nu Holdings' 84.8% return over three years puts recent shareholders in a strong position. This raises the question of how much upside is left from here. Recent progress on full banking licenses in Brazil and Mexico can support expectations for...
NYSE:RH
NYSE:RHSpecialty Retail

RH (RH) Stock Still Looks Overvalued Despite Its 74% Five Year Slump

RH stock has had a difficult run over the past few years, and the latest valuation work points to shares trading at a premium, with both a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples indicating the stock screens as overvalued rather than as a clear bargain. RH has declined about 74.0% over the past five years, which means long term shareholders are still sitting on sizeable losses despite shorter term rebounds. Expectations for stronger earnings growth...
NYSE:VST
NYSE:VSTRenewable Energy

Vistra (VST) Stock Looks Fairly Valued As AI Power Limits Emerge

Vistra stock has delivered an extremely strong 5 year return, but after that run the valuation screens now point to something closer to a middle ground than a clear bargain or clear excess. Over the last 5 years, Vistra has returned about 8.4x an initial investment, which puts extra focus on whether the current price still reflects its fundamentals. Growing attention on power demand from data centers and AI infrastructure can support long term earnings expectations for Vistra, while...
NasdaqGS:HUT
NasdaqGS:HUTSoftware

Can Hut 8 (HUT) Justify Its Valuation After Fully Leasing Beacon Point?

Hut 8 (NasdaqGS:HUT) is in focus after finalizing a second 15 year lease for 352 MW of IT capacity at its Beacon Point AI data center campus in Texas, fully commercializing the 1 gigawatt site. See our latest analysis for Hut 8. The Beacon Point news lands after a volatile year for Hut 8, with a 39.47% 90 day share price return, a year to date share price return of 114.28%, and a very large 1 year total shareholder return of 407.44%. This suggests momentum has been building despite a 30 day...
NYSE:VICI
NYSE:VICISpecialized REITs

High Yield Dividend Stocks With Balance Sheet Strength Worth Watching

Big Tech’s rush to issue AI-related debt is pouring hundreds of billions into the bond market, helping push long-term Treasury yields toward 5% and making risk free income look more appealing. That shift can weigh on share prices; yet it also shines a spotlight on high-yield dividend stocks with at least 3% yields, moderate risk scores, and manageable leverage. For investors who want income but are cautious about heavy borrowing costs, this screen surfaces companies that may handle higher...
NYSE:AR
NYSE:AROil and Gas

Is Antero Resources (AR) Using FERC Pipeline Oversight to Quietly Reshape Its Market Access Strategy?

In July 2026, Antero Resources filed multiple motions to intervene at the Federal Energy Regulatory Commission in proceedings involving Gulf Coast Express, Columbia Gulf Transmission, and Natural Gas Pipeline Company of America, reflecting its interest in tariff changes and new transportation capacity affecting its long-term firm service agreements. These interventions highlight how Antero closely manages its exposure to interstate pipeline terms and capacity expansions that influence market...
NYSE:LOW
NYSE:LOWSpecialty Retail

Lowe's (LOW) Stock May Be 10% Undervalued On AI Growth Plans

Lowe's Companies has had a soft start to 2026, with the share price down 17.2% year to date, while both intrinsic value checks and market multiples currently point to the stock trading below what its cash flows may justify. For investors, that sets up a clear tension between recent share price weakness and valuation signals that lean supportive. The stock has declined 17.2% so far this year, which means sentiment has cooled even as the long term business case is still being...
NasdaqGS:JBLU
NasdaqGS:JBLUAirlines

JetBlue Airways (JBLU) Could Be 88% Undervalued As LaGuardia Slots Raise The Stakes

JetBlue Airways (JBLU) recently won an auction for a package of LaGuardia Airport takeoff and landing slots previously held by Spirit Airlines, giving the carrier room to expand its New York presence. See our latest analysis for JetBlue Airways. At a share price of US$5.16, JetBlue Airways has seen pressure in the near term, with the 7 day share price return down 7.69% and the 30 day share price return down 6.01%. This is occurring even though the year to date share price return of 12.42% and...
NYSE:ASAN
NYSE:ASANSoftware

Asana (ASAN) Loses Chief Accounting Officer, Is The Stock Still Trading At A Discount?

Resignation of Asana’s Chief Accounting Officer Asana (ASAN) recently disclosed that Chief Accounting Officer and Principal Accounting Officer Veronica Sosa has resigned, with her departure effective August 7, 2026, following a transition period in her current role. The company stated that Sosa’s resignation did not arise from any disagreements with Asana regarding operations, policies, practices, or accounting matters, which may guide how investors interpret this leadership change. See our...